Glial Cell Line-Derived Neurotrophic Factor (GDNF)

Subscribe to Selected New Research on Glial Cell Line-Derived Neurotrophic Factor

828 relevant articles (63 outcomes, 135 trials/studies) found for this Bio-Agent

Description: The founding member of the glial cell line-derived neurotrophic factor family. It was originally characterized as a NERVE GROWTH FACTOR promoting the survival of MIDBRAIN dopaminergic NEURONS, and it has been studied as a potential treatment for PARKINSON DISEASE.

Also Known As:

GDNF; GDNF Growth Factor; Glial Cell-Line Derived Neurotrophic Factor; Glial Cell Line Derived Neurotrophic Factor; Growth Factor, GDNF

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Intercellular Signaling Peptides and Proteins: 9177

Nerve Growth Factors: 1298

Glial Cell Line-Derived Neurotrophic Factors: 13

Glial Cell Line-Derived Neurotrophic Factor: 828

human GDNF protein

mouse Gdnf protein

rat Gdnf protein

recombinant TAT-glial line-derived neurotrophic factor fusion protein

zebrafish gdnf protein

Nerve Tissue Proteins: 2

Nerve Growth Factors: 1298

Glial Cell Line-Derived Neurotrophic Factors: 13

Glial Cell Line-Derived Neurotrophic Factor: 828

human GDNF protein

mouse Gdnf protein

rat Gdnf protein

recombinant TAT-glial line-derived neurotrophic factor fusion protein

zebrafish gdnf protein

Peptides: 16375

Intercellular Signaling Peptides and Proteins: 9177

Nerve Growth Factors: 1298

Glial Cell Line-Derived Neurotrophic Factors: 13

Glial Cell Line-Derived Neurotrophic Factor: 828

human GDNF protein

mouse Gdnf protein

rat Gdnf protein

recombinant TAT-glial line-derived neurotrophic factor fusion protein

zebrafish gdnf protein

Biological Factors: 931

Intercellular Signaling Peptides and Proteins: 9177

Nerve Growth Factors: 1298

Glial Cell Line-Derived Neurotrophic Factors: 13

Glial Cell Line-Derived Neurotrophic Factor: 828

human GDNF protein

mouse Gdnf protein

rat Gdnf protein

recombinant TAT-glial line-derived neurotrophic factor fusion protein

zebrafish gdnf protein

Experts

1.	Sawai, Hirozumi: 6 articles (07/2007 - 08/2003)
2.	Okada, Yuji: 6 articles (07/2007 - 08/2003)
3.	Abe, K: 6 articles (03/2003 - 12/2000)
4.	Suzuki, Hidenori: 5 articles (07/2008 - 03/2003)
5.	Funahashi, Hitoshi: 5 articles (07/2007 - 08/2003)
6.	Manabe, Tadao: 5 articles (07/2007 - 08/2003)
7.	Georgievska, Biljana: 5 articles (06/2007 - 02/2004)
8.	Kiuchi, Kazutoshi: 5 articles (09/2006 - 01/2002)
9.	Aebischer, P: 5 articles (11/2004 - 01/2000)
10.	Lang, Anthony E: 4 articles (07/2007 - 02/2006)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 04/01/2006 - "Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease." 01/15/1999 - "Recent studies suggest that these GDNF gene therapy approaches are effective in rat models of Parkinson's disease. " 10/01/2003 - "Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease." 01/26/1995 - "Our findings suggest that GDNF or related molecules may be useful for the treatment of Parkinson's disease." 06/01/2006 - "A recent clinical study showed that intraputaminal infusions of GDNF restored the striatal dopaminergic function, resulting in improvement in patients with Parkinson disease. " Order ALL the reference details at left...
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 02/01/2009 - "Development of drug delivery technologies facilitating controlled release of GDNF is critical to applying GDNF in treating neurodegenerative diseases. " 07/01/2008 - "However, the actual role of endogenous GDNF in the normal adult brain is unknown, even though GDNF-based therapies are considered promising for neurodegenerative disorders. " 11/01/2006 - "The identification of a GDNF-mediated, autoregulatory long-lasting feedback loop could have important implications for GDNF's potential value as a treatment for addiction and neurodegenerative diseases." 07/01/1999 - "Recombinant human glial cell line-derived neurotrophic factor has been implicated to have therapeutic potential in the treatment of neurodegenerative diseases. " 02/01/1999 - "These experiments suggest that GDNF may provide significant therapeutic opportunities in several neurodegenerative disorders." Order ALL the reference details at left...
3.	Brain Injuries (Brain Injury) 03/01/2001 - "These results suggest that the successful exogenous GDNF gene transfer ameliorates the ischemic brain injury after transient MCAO in association with the reduction of apoptotic signals. " 12/01/1999 - "These results suggest that the successful exogenous GDNF gene transfer ameliorates ischemic brain injury after transient MCAO in association with the reduction of apoptotic signals." 05/01/2002 - "Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury." 10/01/2001 - "Protective effects of glial cell line-derived neurotrophic factor on hippocampal neurons after traumatic brain injury in rats." 11/01/2002 - "Spatial and temporal changes in the pattern of GDNF expression following injury, as determined in this study may provide insight into the functions of GDNF in vivo and into possible therapeutic approaches toward prevention of damage or rescue of neurons following brain injury." Order ALL the reference details at left...
4.	Pain (Aches) 10/06/2000 - "Together these findings provide a rational basis for the use of GDNF as a therapeutic treatment for neuropathic pain states." 03/01/2006 - "The present study demonstrated that endogenous GDNF and GFRalpha-1 might play an anti-hyperalgesic role in neuropathic pain of rats. " 03/11/2005 - "Using immunohistochemistry, Western blot, and RT-PCR analysis techniques, the present study observed the effects of EA on the expression of GDNF and GDNF family receptor alpha-1 (GFRalpha-1, the high-affinity receptor of GDNF) in neuropathic pain rats. " 07/15/2008 - "GDNF also exhibits analgesic effects in rodent models of neuropathic pain, although the underlying mechanisms are still largely unknown, including the intracellular signal transduction involved. " 10/01/2006 - "Both allodynia- and CGRP/GAP43-positive afferent sprouting were less in the C17.2/GDNF group compared to the C17.2 group, suggesting a possible protective or analgesic effect of GDNF on post-injury neuropathic pain." Order ALL the reference details at left...
5.	Wounds and Injuries (Trauma) 12/01/2001 - "The present study shows that adenoviral GDNF delivery is protective in focal cortex trauma." 10/01/2003 - "This work demonstrates that intracerebral adeno-viral mediated GDNF gene transfer can protect dopaminergic neurons in vivo from 6-OHDA-induced injuries. " 05/01/2002 - "Using viral-mediated gene transfer, we overexpressed transgenic glial cell line-derived neurotrophic factor and demonstrated a robust protective effect against acoustic and ototoxic inner ear trauma. " 11/01/2000 - "Apoptosis in auditory brainstem neurons after a severe noise trauma of the organ of Corti: intracochlear GDNF treatment reduces the number of apoptotic cells." 03/20/1999 - "Our results demonstrate the feasibility of gene therapy for cochlear application and suggest that virus-mediated overexpression of GDNF may be developed as a valuable prevention against trauma-induced HC death." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Glial Cell Line-Derived Neurotrophic Factor (GDNF)
2.	Brain-Derived Neurotrophic Factor (BDNF)
3.	Dopamine (Intropin)
4.	Nerve Growth Factor (NGF)
5.	Nerve Growth Factors (Neurotrophins)
6.	Neurturin
7.	Oxidopamine (6 Hydroxydopamine)
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.	Retinaldehyde (Retinal)
10.	1-Phosphatidylinositol 3-Kinase (PI 3 Kinase)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Transplants (Transplant)
3.	Tissue Therapy (Cell Therapy)
4.	Microspheres (Microsphere)
5.	Injections

Best Treatments:
Research Summary Report
on Parkinson Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1228 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>